Intranasal esketamine delivery in psychiatric care — the S-enantiomer of ketamine administered via nasal spray for rapid-acting antidepressant effects in treatment-resistant depression (TRD) and major depressive disorder with acute suicidal ideation representing the first novel antidepressant mechanism in decades — creates the most paradigm-shifting market opportunity, with the...